16th Annual Hypertension Conference: Focus on Hypertension, Diabetes and Dyslipidemia

Gaps in the level of Hemoglobin A1C, BP, and LDL-Cholesterol reduction continue to occur in high-risk individuals with Type 2 diabetes, Hypertension, and Dyslipidemia, respectively. Recent results from the ACCORD, VADT, and ADVANCE studies suggest the benefits on reducing macrovascular disease events are unclear and, in fact, caution should be exercised when reducing Hemoglobin A1C in those with long standing Type 2 diabetes to a goal of < 6% when compared to a goal between 7 and 7.9%. In addition, controversy continues from recent guidelines on the level of LDL-cholesterol and BP reduction that can be and should be achieved. This conference will address these and other issues confronting the clinician who treats patients with diabetes, hypertension, and dyslipidemia. The participant will learn the most current information on these issues and will be able to transport these clinical principles back to their every day practice to improve patient care.

OBJECTIVES
At the completion of this activity, participants should be better prepared to:

• Discuss goals, medications and controversies surrounding management of patients with Diabetes, Hypertension and Dyslipidemia;

• Describe appropriate treatment plans for these individuals; and

• Apply new learning to improve health outcomes involving patients with Diabetes, Hypertension, and Dyslipidemia.
+ show speakers and program
Review of Conference Purpose and Objectives

J. Basile, MD

THEME 1: FOCUS ON DIABETES



1:00 – 1:45 pm

Individualizing A1C Goals in Diabetes: A Perspective From Recent Clinical Trials

M. Whitaker, MD

1:45 – 2:30 pm

New Drug Update-Contrasting the Diabetic, Hypertension, and Lipid Landscape

W. Weart, PharmD

2:30 – 2:45 pm

BREAK



2:45 – 3:30 pm

New Drug Update-Contrasting the Diabetic, Hypertension, and Lipid Landscape (Con’t)

W. Weart, PharmD

3:30 – 4:15 pm

From Pre-Diabetes to Diabetes: Utilizing Oral, Incretin, and Insulin Therapies

M. Whitaker, MD

4:15 – 5:15 pm

Cases in Diabetes

M. Whitaker/ W. Weart





SATURDAY July 28, 2012


7:00 am

Continental Breakfast



7:20 – 7:30 am

Review of Yesterday’s Key Points

J. Basile, MD

THEME 2: HYPERTENSION

BREAK



7:30 – 8:00 am

Does Risk Assessment Add Value to Clinical Assessment When Treating Hypertension

D. Lackland, MD

8:00 – 8:30 am

What We Need to Know About Pre-hypertension: Preventing and Treating

B. Egan, MD

8:30 – 9:00 am

What Should JNC8 look like: Antihypertensive Agents and BP Goals

J. Basile, MD

9:00 – 9:45 am

The Importance of Microalbuminuria and Clinical Proteinuria: Are they targets for Specific Antihypertensive Rx?

M. Weir, MD

9:45 – 10:00 am

BREAK


10:00 – 10:30 am

Combination AntihypertensiveTherapy-What are the Options and Why Should We Use Them

J. Basile, MD

10:30 – 11:15 am

Managing Treatment Resistant Hypertension: A View from NHANES and O’QUIN

B. Egan, MD

11:15 – 11:45 am

Treatment of Hypertension in the Dialysis and Transplant Patient

M. Weir, MD

11:45 am – 1:00 pm

Hypertension Cases

J. Brzezenski

1:00 – 1:30 pm

Lunch


1:30 – 3:30 pm

Atrial Fibrillation and Stroke Prevention: An interactive simulation-based workshop

J. Basile







SUNDAY July 29, 2012


7:00 am

Continental Breakfast



7:20 – 7:30 am

Review of Yesterday’s Key Points

J. Basile, MD

THEME 3: Dyslipidemia

BREAK



7:30 – 8:30 am

Understanding the Controversial Issues That Will Affect ATP4

P. Jones, MD

8:30 – 9:15 am

Approach to the Patient with Low HDL-C

J. Underberg, MD

9:15 – 10:00 am

Appropriate Use of Advanced Lipid and non-Lipid Biomarkers Testing for Risk Assessment

P. Jones, MD

10:00 – 10:15 am

Break


10:15 – 11:00 am

Approach to the Patient with High Triglycerides

J. Underberg

11:00 – 12:15 pm

Lipids Cases

P. Jones/ J. Underberg

27 Jul - 29 Jul 2012
palm coast
United States of America
meeting website